

Wider access to cancer drugs

Catherine Foot, Senior Fellow


Britain Against Cancer conference

1st December 2009

Aims of breakout session

- › Introduce the relevant recommendations from the APPG report
- › Suggests possible additional or alternative recommendations
- › Discuss and vote on these recommendations, as well as proposing new ones of our own

The (simplified) pathway of a new drug



Why NICE recommendations are not always in the patient's best interests

NCRI should publish balance of research portfolio by cancer type

Ultra-orphan drugs should be commissioned by the National Specialised Commissioning Group

New national fund for 'near label' treatments for extremely rare cancers

Flexible approach to orphan drugs

Provide emotional support

Research and trials

Licensing

Appraised by NICE

Not appraised by NICE

Approved

Failed

Local decision to make funding available to all suitable patients in the area

Individual patients can apply to exceptional case review

Cost

Drug available to patients

Options

NICE, NCRI and industry should work together to ensure that **NICE research recommendations** are taken forward after a negative appraisal decision

NCRN should publish the **age** profiles of patients in trials and encourage more trials for both young and older people

Research and trials

Licensing

Appraised by NICE

Not appraised by NICE

PCTs should have more **expert advice** on the clinical and cost-effectiveness of non-NICE appraised drugs

Increase the **overall NHS budget** for new drugs

Increase use of **oncologist and clinician opinion** and advice in NICE appraisal process

Failed

Local decision to make funding available to all suitable

Individual patients can apply to exceptional case review

Cost

Drug available to patients

Guidance is needed for PCTs to make exceptional case reviews more **consistent and transparent**

The government should work with industry to make drugs cheaper for the NHS, at least initially, through **value-based pricing and cost-sharing**

Discussion and voting

- › Discuss in pairs:
 1. What's most important and why?
 2. What else should be done?
- › Questions and comments
- › Then: vote using your three stickers
- › Further discussion

The recommendations

Research and trials

1. NCRI should publish the balance of its partners' research portfolio by cancer type
2. NICE, NCRI and industry should work together to ensure that NICE research recommendations are taken forward after a negative appraisal decision
3. NCRN should publish the age profiles of patients in trials and encourage more trials for both young and older people

NICE appraisal process

4. NICE should adopt a flexible approach to appraising orphan drugs
5. Increase use of oncologist and clinician opinion and advice in NICE appraisal process

Non-NICE appraised drugs

6. Ultra-orphan drugs should be commissioned by the National Specialised Commissioning Group
7. New national fund for 'near label' treatments for extremely rare cancers
8. PCTs should have more expert advice on the clinical and cost-effectiveness of non-NICE appraised drugs

Exceptional case review process

9. Emotional support should be provided for patients going through exceptional case review
10. Guidance is needed for PCTs to make exceptional case reviews more consistent and transparent

Drug costs

11. The government should work with industry to make drugs cheaper for the NHS, at least initially, through value-based pricing and cost-sharing
12. Increase the overall NHS budget for new drugs